Investigator Alex Diederichsen, PhD recaps the results of DANCAVAS trial, which found that after more than 5 years, the invitation to undergo comprehensive cardiovascular screening and treatment if detected did not significantly reduce the incidence of death from any cause among men 65 to 74 years of age.